Quarterly results round-up: Illumina better than expected, Thermo Fisher raises guidance
This article was originally published in Clinica
Gene sequencing firm Illumina reported better-than-expected results for its first fiscal quarter. Revenues of $272.7m were above its previous guidance of $250-260m, as per the preliminary results the company posted earlier this month when it forecast revenues of around $270m (www.clinica.co.uk, 3 April 2012). However, sales were down 3% compared with last year's Q1.